Trial Profile
A Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Selpercatinib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoid tumour; Carcinoma; Cholangiocarcinoma; Colon cancer; Large cell carcinoma; Medullary thyroid cancer; Neuroendocrine carcinoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Rectal cancer; Salivary gland cancer; Sarcoma; Skin cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Acronyms LIBRETTO-001
- Sponsors Loxo Oncology
- 20 Jan 2024 Results(n=52, data cut-off: 13Jan2023) presented at the 2024 Gastrointestinal Cancers Symposium
- 17 Jan 2024 Planned End Date changed from 1 Sep 2024 to 28 Feb 2026.
- 17 Jan 2024 Planned primary completion date changed from 21 Mar 2024 to 28 Feb 2025.